Disease landscape

Acute Myeloid Leukemia (AML) clinical trials

Get alerts when Acute Myeloid Leukemia (AML) trials change

947 active trials 564 recruiting 89 Phase 3 389 sponsors 147 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-09-05

What changed in the last 30 days showing 52 of 147 changes on 20 trials

2026-08-28
Recruitment suspended
Recruitment suspended: Unacceptable Toxicity
NCT03816319 TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or… · National Cancer Institute (NCI) · Phase 1
2026-08-25
Trial terminated
Primary completion moved earlier: 2028-07-31 → 2026-07-01
Completion moved earlier: 2029-12-31 → 2026-07-31
NCT04010877 Multiple CAR-T Cell Therapy Targeting AML · Shenzhen Geno-Immune Medical Institute · Phase 1/2
2026-08-27
Withdrawn before enrolling
Trial withdrawn: Strategic adjustment.
Enrollment reduced: 10 → 0 participants
Primary completion moved earlier: 2028-10-31 → 2026-03-30
Completion moved earlier: 2028-10-31 → 2026-03-30
NCT07338357 Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML · First Affiliated Hospital of Guangxi Medical University · Early Phase 1
2026-08-22
Recruitment suspended
Recruitment suspended: Accrual goal met
NCT03728335 Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation · City of Hope Medical Center · Phase 2
2026-08-21
Trial terminated
Trial terminated: \<75% participants
Primary completion moved earlier: 2026-11-30 → 2026-08-14
Completion moved earlier: 2026-11-30 → 2026-08-14
NCT02392572 ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk… · M.D. Anderson Cancer Center · Phase 1/2
2026-08-07
Trial terminated
Trial terminated: The study was closed due to the end of funding.
NCT04994808 Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem… · Fred Hutchinson Cancer Center · Phase 2
2026-08-11
Recruitment suspended
Recruitment suspended: Recruitment on hold with plans to open to accrual again soon.
NCT06492707 DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse… · Fred Hutchinson Cancer Center · Phase 1
2026-09-04
Primary completion pushed: 2026-05-31 → 2026-10-15
Completion pushed: 2026-08-31 → 2026-11
NCT04635384 Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT)… · CareDx
2026-09-04
Primary completion pushed: 2028-12 → 2032-12
Primary endpoint(s) modified
Phase changed: Phase 1/2 → Phase 2/3
Interventions modified
Trial sites expanded: 19 → 31 locations
Completion pushed: 2028-12 → 2032-12
Trial arms changed: 18 → 23
NCT03013998 Study of Biomarker-Based Treatment of Acute Myeloid Leukemia · Beat AML, LLC · Phase 2/3
2026-08-21
Primary completion pushed: 2027-09-16 → 2032-04-05
NCT02386800 CINC424A2X01B Rollover Protocol · Novartis Pharmaceuticals · Phase 4
2026-09-03
Primary completion pushed: 2028-12 → 2029-09
Recruitment opened
Trial sites expanded: 4 → 17 locations
Completion pushed: 2028-12 → 2029-09
NCT07025824 Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With… · Technische Universität Dresden · Phase 2
2026-09-02
Primary completion pushed: 2026-06-23 → 2027-05-11
Completion pushed: 2026-06-23 → 2027-05-11
NCT04262843 Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell… · City of Hope Medical Center · Phase 2
2026-08-21
Primary completion pushed: 2026-08 → 2026-12
NCT06001788 Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory… · Kura Oncology, Inc. · Phase 1
2026-09-03
Primary completion pushed: 2025-12-31 → 2030-02
Completion pushed: 2025-12-31 → 2030-02
NCT04953780 Phase 1 of Calaspargase Pegol-mknl W/ Cytarabine and Idarubicin in Newly Diagnosed AML · West Virginia University · Phase 1
2026-08-28
Primary completion pushed: 2025-06 → 2026-03-31
Completion pushed: 2026-12 → 2027-12
NCT05153226 GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG · DKMS gemeinnützige GmbH · Phase 3
2026-09-03
Primary completion pushed: 2026-07-01 → 2027-07-01
Completion pushed: 2026-12-31 → 2027-12-31
NCT05772273 PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT · The First Affiliated Hospital of Soochow University
2026-08-18
Primary completion pushed: 2026-02-01 → 2026-12-24
Completion pushed: 2026-06-30 → 2026-12-30
NCT06001385 HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced… · Center for International Blood and Marrow Transplant Research · Phase 2
2026-08-28
Primary completion pushed: 2028-09 → 2030-09
Completion pushed: 2028-09 → 2030-09
NCT05904106 Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly… · Technische Universität Dresden · Phase 2
2026-08-27
Primary completion pushed: 2026-08-06 → 2027-07-14
Completion pushed: 2026-08-06 → 2027-07-14
NCT02159495 Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory… · City of Hope Medical Center · Phase 1
2026-08-27
Primary completion pushed: 2026-09-30 → 2028-07-31
Trial status changed: Recruiting → Not Yet Recruiting
Completion pushed: 2026-12-31 → 2028-12-31
NCT05995028 Universal 4SCAR7U Targeting CD7-positive Malignancies · Shenzhen Geno-Immune Medical Institute · Phase 1

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-09-04 NCT07805096 Efficacy of a Smart Holistic Health Care Platform Intervention on Cancer Children and… National Defense Medical University, Taiwan new
2026-09-03 NCT07802015 Home-based Intravenous Cytarabine Treatment for Acute Myeloid Leukemia: a National Danish… Zealand University Hospital new
2026-08-19 NCT07773909 Venetoclax With Hypomethylating Agents in Newly Diagnosed AML Unfit for Intensive… Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh new Phase 4
2026-08-18 NCT07771803 A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia… Roger Strair new Early Phase 1
2026-08-17 NCT07766850 Addition of Hydroxyurea to Fludarabine, Cytarabine, Idarubicin and Venetoclax Salvage… Christer C Nilsson new Phase 1/2
2026-08-13 NCT07763054 Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia… Haikou Affiliated Hospital of Central South University Xiangya School of Medicine new
2026-08-12 NCT07761533 PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS Chaser Therapeutics, Inc. new Phase 1/2
2026-08-10 NCT07755202 Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With… Florian Kuchenbauer new Phase 2
2026-08-07 NCT07751991 A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML Charm Therapeutics new Phase 1
2026-08-06 NCT07749976 GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL… Vitruviae new Phase 1/2

Active trials by phase

Early Phase 1
25
Phase 1
253
Phase 1/2
117
Phase 2
261
Phase 2/3
25
Phase 3
64
Phase 4
8
Not charted: 194 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 947

NCT IDTitleSponsorStatusUpdated
Phase 4
NCT07044687 Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in… AbbVie Recruiting 2026-08-14
NCT07486713 Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies Rigel Pharmaceuticals Recruiting 2026-08-11
NCT06370000 Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML)… Virginia Commonwealth University Recruiting 2026-05-29
NCT07561892 Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating… Fujian Medical University Union Hospital Recruiting 2026-05-01
NCT06571825 RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR He Huang Recruiting 2024-08-26
NCT02386800 CINC424A2X01B Rollover Protocol Novartis Pharmaceuticals Active, Not Recruiting 2026-08-20
NCT05144243 Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in… AbbVie Active, Not Recruiting 2025-08-12
NCT06763666 CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML Nanfang Hospital, Southern Medical University Not Yet Recruiting 2025-01-08
Phase 3
NCT07022678 Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With… Children's Oncology Group Recruiting 2026-09-04
NCT06652438 Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or… Stichting Hemato-Oncologie voor Volwassenen Nederland Recruiting 2026-09-02
NCT07223814 Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by… Stichting Hemato-Oncologie voor Volwassenen Nederland Recruiting 2026-09-01
NCT07478991 Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients… PETHEMA Foundation Recruiting 2026-08-31
NCT07211958 Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute… Syndax Pharmaceuticals Recruiting 2026-08-28
NCT04628026 Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients… University of Ulm Recruiting 2026-08-24
NCT05183035 Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) PedAL BCU, LLC Recruiting 2026-08-24
NCT07007312 Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With… Kura Oncology, Inc. Recruiting 2026-08-20
NCT07514936 Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With… Chinese PLA General Hospital Recruiting 2026-08-20
NCT06713837 IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute… Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS Recruiting 2026-08-14
NCT06744504 Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid… Institute of Hematology & Blood Diseases Hospital, China Recruiting 2026-08-07
NCT04293562 A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for… Children's Oncology Group Recruiting 2026-07-29
NCT07702578 A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic… TScan Therapeutics, Inc. Recruiting 2026-07-22
NCT07712848 DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML The Second Affiliated Hospital of Kunming Medical University Recruiting 2026-07-20
NCT05429632 Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT Priothera SAS Recruiting 2026-07-17
NCT05907057 An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult… Servier Affaires Médicales Recruiting 2026-05-08
NCT05586074 HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML Sunshine Lake Pharma Co., Ltd. Recruiting 2026-04-28
See all 947 active Acute Myeloid Leukemia (AML) trials with filters →

Top sponsors by active trials in this area

M.D. Anderson Cancer Center (56) · Institute of Hematology & Blood Diseases Hospital, China (42) · National Cancer Institute (NCI) (35) · City of Hope Medical Center (32) · The First Affiliated Hospital of Soochow University (28) · Fred Hutchinson Cancer Center (14) · Peking University People's Hospital (13) · Ruijin Hospital (13) · AbbVie (12) · First Affiliated Hospital of Zhejiang University (12)

Get alerts when Acute Myeloid Leukemia (AML) trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free